🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chemnitz
Clinical trial register · Germany

Clinical Trials in Chemnitz, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 Hoffmann-La Roche10 Bristol-Myers Squibb7 AbbVie6 Eli Lilly and Company5
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Chemnitz

166 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse
NCT05042453Pelvic Organ Prolapse
Promedon
Observational
140
Chemnitz, Erfurt, Freiburg im Breisgau, Kassel, Leipzig, Mannheim, Tettnang
2022-12-19
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916Breast Cancer
Greenwich LifeSciences, Inc.
Phase 3
2,250
Augsburg, Bayreuth, Berlin, Bottrop, Braunschweig, Bremen, Chemnitz, Dessau
2022-12-16
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
213
Chemnitz, Hamburg, Tübingen
2022-12-15
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
DrugsCapmatinib·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
57
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2022-12-13
Recruiting
GMMG Multiple Myeloma Registry
NCT07111884Multiple Myeloma
Prof. Dr. Hartmut Goldschmidt
Observational
999
Berlin, Bielefeld, Bochum, Bonn, Chemnitz, Cologne, Darmstadt, Düsseldorf
2022-12-08
Recruiting
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
NCT05695508Multiple Myeloma
DrugsRamantamig·Talquetamab·Teclistamab·Bortezomib
University of Heidelberg Medical Center
Phase 2
160
Berlin, Chemnitz, Dresden, Düsseldorf, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2022-12-01
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,060
Freiburg im Breisgau, Tübingen, Ulm, Mainz, Aachen, Braunschweig, Chemnitz, Hamburg
2022-11-10
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
DrugsTucatinib·Erbitux·Herceptin·Avastin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Munich, München, Hanover, Leipzig, Amberg, Berlin, Chemnitz, Dresden
2022-10-24
Active, closed
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
NCT05582902MDS, MDS/MPN
University of Leipzig
Observational
60
Berlin, Chemnitz, Dresden, Düsseldorf, Jena, Leipzig, Mainz, Mannheim
2022-10-11
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891Cancer
EMD Serono Research & Development Institute, Inc.
Observational
700
Chemnitz, Großhansdorf, Heidelberg, Löwenstein
2022-10-04
Recruiting
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05009082Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
DrugsNiraparib·Paclitaxel·Bevacizumab·Carboplatin
AGO Study Group
Phase 3
970
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Brandenburg an der Havel, Bremen, Chemnitz
2022-09-13
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
341
Berlin, Chemnitz, Frankfurt A. Main, Gauting, Immenhausen, Löwenstein, München, Münster
2022-08-03
Active, closed
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974Non-small Cell Lung Cancer
DrugsParaplatin·Sacituzumab Govitecan·Keytruda·Cisplatin
Gilead Sciences
Phase 2
193
Berlin, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Halle
2022-05-30
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Tübingen, Ulm, Bayreuth, Munich, Westerstede, Düsseldorf, Chemnitz, Leipzig
2022-05-03
Active, closed
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348Multiple Myeloma
DrugsElotuzumab·Selinexor·Pomalidomide·Dexamethasone
European Myeloma Network B.V.
Phase 3
117
Chemnitz, Düsseldorf, Greifswald, Hamburg
2022-04-19
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Bonn, Chemnitz, Dresden, Düsseldorf, Frankfurt, Göttingen, Hamburg, Hanover
2022-03-28
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Würzburg, Mainz, Leipzig, Kiel, Berlin, Chemnitz, Essen, München
2022-03-25
Active, closed
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT05153226Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS
DrugCyclophosphamide
DKMS gemeinnützige GmbH
Phase 3
640
Aachen, Augsburg, Chemnitz, Cologne, Dortmund, Dresden, Düsseldorf, Essen
2022-03-02
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
DrugsDomvanalimab·Durvalumab
AstraZeneca
Phase 3
791
Berlin, Berlin-Zehlendorf, Braunschweig, Chemnitz, Cologne, Erlangen, Essen, Giessen
2022-02-18
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
DrugObicetrapib
NewAmsterdam Pharma
Phase 3
9,541
Bad Homburg, Berlin, Bremen, Chemnitz, Dortmund, Dresden, Elsterwerda, Erfurt
2022-02-07
Recruiting
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043Multiple Myeloma, Plasma Cell Disorder
DrugHDP-101
Heidelberg Pharma AG
Phase 1/2
78
Berlin, Chemnitz, Cologne, Hamburg, Heidelberg, Kiel, Lübeck, Mainz
2022-02-07
Recruiting
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
NCT05008809Colorectal Cancer
DrugsMFOLFOXIRI·MFOLFOX6·Folfiri·Folfox
Dominik Paul Modest
Phase 3
507
Amberg, Bad Saarow, Bayreuth, Berlin, Bochum, Bonn, Bremen, Chemnitz
2021-12-06
Active, closed
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab
Hoffmann-La Roche
Phase 3
660
Bad Berka, Berlin, Chemnitz, Essen, Georgsmarienhütte, Großhansdorf, Halle, Immenhausen
2021-11-18
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab
Pfizer
Phase 3
893
Ulm, Würzburg, Berlin, Braunschweig, Chemnitz, München
2021-10-04
Active, closed
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136Primary Biliary Cholangitis, PBC
DrugVolixibat
Mirum Pharmaceuticals, Inc.
Phase 2
333
Chemnitz, Frankfurt, Hanover, Kiel, Leipzig, Magdeburg, Münster, Tübingen
2021-09-22
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Truxima·Venclyxto
Loxo Oncology, Inc.
Phase 3
600
Chemnitz, Essen, Kerpener, Koelner Platz 1, Leipzig, Rostock, Würzburg
2021-09-20
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Karlsruhe, Augsburg, Berlin, Chemnitz, Erlangen, Essen, Georgsmarienhütte, Hamburg
2021-08-27
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Wiesbaden, Mainz, Homburg, Chemnitz, Dresden, Leipzig, Lübeck, Berlin
2021-08-19
Recruiting
European Disease Registry on Retinopathy of Prematurity (ROP)
NCT04939571Retinopathy of Prematurity
University Medicine Greifswald
Observational
3,000
Aachen, Berlin, Bonn, Braunschweig, Chemnitz, Cologne, Cottbus, Düsseldorf
2021-08-06
Active, closed
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370Pulmonary Embolism
Boston Scientific Corporation
Phase 4
544
Aachen, Bielefeld, Bonn, Chemnitz, Freiburg im Breisgau, Immenstädt, Lübeck, Mainz
2021-08-02
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib
AstraZeneca
Phase 3
315
Ansbach, Augsburg, Bonn, Chemnitz, Dresden, Erlangen, Essen, Freiburg im Breisgau
2021-06-30
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone
Incyte Corporation
Phase 3
899
Aachen, Augsburg, Berlin, Bonn, Chemnitz, Cottbus, Göttingen, Halle
2021-05-11
Recruiting
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905Acute Hepatic Porphyria
Alnylam Pharmaceuticals
Observational
150
Berlin, Chemnitz, Würzburg
2021-04-26
Recruiting
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
NCT05331521Oligodendroglioma
DrugProcarbazine
University Hospital Heidelberg
Phase 3
406
Heidelberg, Berlin, Bochum, Bonn, Chemnitz, Cologne, Düsseldorf, Frankfurt
2021-04-07
Active, closed
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007Myelofibrosis
DrugsBMS-986158·Fedratinib·Ruxolitinib
Bristol-Myers Squibb
Phase 1/2
216
Erding, Essen, Chemnitz, Halle, Lübeck
2021-03-22
Active, closed
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04229979Acute Myeloid Leukemia
DrugsSargramostim·Gm-Csf·Ara-C·Decitabine
Sellas Life Sciences Group
Phase 3
127
Chemnitz, Leipzig, Rostock
2021-02-08
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Augsburg, Berlin, Bielefeld, Böblingen, Braunschweig, Bremen, Chemnitz, Cologne
2020-12-04
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Immenstadt im Allgäu, Amberg, Augsburg, Bad Homburg, Berlin, Braunschweig, Chemnitz, Cologne
2020-12-02
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Palbociclib·Letrozole
Hoffmann-La Roche
Phase 3
992
Berlin, Chemnitz, Dresden, Essen, Georgsmarienhütte, Göttingen, Hamburg, Hanover
2020-10-09
Recruiting
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
NCT04385290Acute Myeloid Leukemia
DrugsMidostaurin·Daunorubicin
Technische Universität Dresden
Phase 1/2
214
München, Essen, Aachen, Augsburg, Chemnitz, Dresden, Frankfurt am Main, Halle
2020-09-04
Active, closed
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04468984Myelofibrosis (MF)
DrugsNavitoclax·Ruxolitinib
AbbVie
Phase 3
330
Mannheim, Mutlangen, Augsburg, Rostock, Bochum, Chemnitz, Dresden, Hamburg
2020-08-31
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
805
Bonn, Chemnitz, Dresden, Leipzig
2020-05-05
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Augsburg, Berlin, Chemnitz, Freiburg im Breisgau, Göttingen, Lingen, Münster, Tübingen
2019-12-17
Recruiting
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
NCT04045691Melanoma Stage IV, Melanoma Stage III
DrugsBinimetinib·Encorafenib
Pierre Fabre Pharma GmbH
Observational
750
Ahaus, Aschaffenburg, Augsburg, Berlin, Bremerhaven, Buxtehude, Chemnitz, Donauwörth
2019-10-17
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494Lymphoblastic Lymphoma, Childhood
DrugsVindesine·Thioguanine·PEG-Asparaginase·Mercaptopurine
University Hospital Muenster
Phase 3
683
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Bremen, Chemnitz
2019-08-23
Active, closed
Frontline Asciminib Combination in Chronic Phase CML
NCT03906292Chronic Myeloid Leukemia
DrugsAsciminib·Nilotinib·Dasatinib·Imatinib
University of Jena
Phase 2
125
Aachen, Berlin, Bonn, Bremen, Chemnitz, Dresden, Erlangen, Essen
2019-08-19
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
908
Berlin, Bonn, Chemnitz, Cologne, Freiburg im Breisgau, Heidelberg, Leipzig, Lübeck
2019-04-29
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
DrugsPomalidomide·Venetoclax·Dexamethasone
AbbVie
Phase 3
265
Stuttgart, Tübingen, Würzburg, Chemnitz, Kiel, Jena, Berlin, Hamburg
2018-10-22
Active, closed
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731Multiple Myeloma
DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide
University of Heidelberg Medical Center
Phase 3
662
Aachen, Bad Saarow, Berlin, Bielefeld, Bochum, Bonn, Braunschweig, Chemnitz
2018-10-18
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
DrugsAlectinib·Vinorelbine·Pemetrexed·Gemcitabine
Hoffmann-La Roche
Phase 3
257
Chemnitz, Georgsmarienhütte, Heidelberg, Immenhausen
2018-08-16
Active, closed
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
NCT03503799Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative Tumor
North Eastern German Society of Gynaecological Oncology
Observational
1,191
München, Berlin, Ansbach, Bremerhaven, Chemnitz, Dresden, Düsseldorf, Ebersberg
2018-07-17
Recruiting
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276Acute Lymphoblastic Leukemia, Pediatric
DrugsBlinatumomab·Daunorubicin·Bortezomib·Cytarabine
Martin Schrappe
Phase 3
5,000
Aachen, Augsburg, Berlin, Braunschweig, Chemnitz, Cologne, Cottbus, Datteln
2018-07-15
Active, closed
Endurant CHevAr New Indication Trial: ENCHANT
NCT03320252AAA - Abdominal Aortic Aneurysm
Medtronic Cardiovascular
Observational
150
Chemnitz, Essen, Frankfurt am Main, Heidelberg, Münster
2017-10-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib
Hoffmann-La Roche
Phase 2/3
1,000
Chemnitz, Gauting, Heidelberg, Wiesbaden
2017-09-22
Active, closed
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
NCT03104842Multiple Myeloma
DrugsIsatuximab·Carfilzomib·Lenalidomide·Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
Phase 2
246
Berlin, Bielefeld, Bonn, Chemnitz, Cologne, Eschweiler, Essen, Hamburg
2017-08-15
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Essen, Chemnitz, Berlin, Hanover, Leipzig, München, Ulm
2017-06-26
Active, closed
REDUCE LAP-HF III Corvia Protocol 1701
NCT03191656Heart Failure
Corvia Medical
Observational
500
Bad Nauheim, Bad Oeynhausen, Bad Segeberg, Berlin, Chemnitz, Cologne, Detmold, Dresden
2017-03-12
Recruiting
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
NCT02880618Heart Failure
CVRx, Inc.
Observational
500
Hamburg, Bad Oeynhausen, Berlin, Bernau, Chemnitz, Cologne, Detmold, Dresden
2016-12-13
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Leipzig, Berlin, Chemnitz, Dresden, Erfurt, Gauting, Gera, Göttingen
2016-09-13
Active, closed
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
NCT02917720Chronic Myeloid Leukemia
DrugNilotinib
European LeukemiaNet
Phase 2
75
Freiburg im Breisgau, Mannheim, München, Hannover, Aachen, Bayreuth, Chemnitz, Esslingen am Neckar
2016-09
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
DrugsHumira·Adalimumab·Upadacitinib
AbbVie
Phase 3
1,629
Cologne, Herne, Rendsburg, Chemnitz, Hamburg, Munich
2015-12-01
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
DrugsGnRH·Bicalutamide·Apalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Braunschweig, Chemnitz, Dessau, Frankfurt, Gronau, Jena, Münster, Nürtingen
2015-11-19
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
DrugsVinorelbine·Tecentriq·Atezolizumab·Pemetrexed
Hoffmann-La Roche
Phase 3
1,280
Bielefeld, Berlin, Braunschweig, Chemnitz, Frankfurt am Main, Großhansdorf, Hemer, Homburg
2015-10-31
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
DrugsGefitinib·Erlotinib·Ramucirumab·Osimertinib
Eli Lilly and Company
Phase 3
545
Gerlingen, Heidelberg, Cologne, Chemnitz, Halle, Großhansdorf, Berlin
2015-05-06
Recruiting
International HIT-MED Registry (I-HIT-MED)
NCT02417324Childhood Brain Tumor
Universitätsklinikum Hamburg-Eppendorf
Observational
500
Aachen, Augsburg, Berlin, Bielefeld, Braunschweig, Bremen, Chemnitz, Cologne
2015-01
Active, closed
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220Brain Tumors
Universitätsklinikum Hamburg-Eppendorf
Phase 2/3
360
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Bremen, Chemnitz
2014-06
Rows per page Showing 101–166 of 166
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/chemnitz?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 166 of those studies with a site in Chemnitz.

How many clinical trials are recruiting in Chemnitz?

90 of the 166 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 3 have not yet opened recruitment, 71 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.